Abstracts tagged "joint damage"

Abstract Number: 1005 • 2014 ACR/ARHP Annual Meeting
Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K27
Feng-Sheng Wang¹, Pe-Chin Chuang¹, Yi-Chih Sun¹, Yu-Shan Chen¹ and Jih-Yang Ko², ¹Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, ²Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan
Background/Purpose: Intensive articular cartilage deterioration and synovial fibrosis in joints are prominently pathogenic features of osteoarthritic (OA) knees. Epigenetic reactions in joint microenvironments are linked…
Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Désirée van der Heijde¹, Robert B. M. Landewé², Philip J. Mease³, Iain B. McInnes⁴, Philip G. Conaghan⁵, Luminita Pricop⁶, Gregory Ligozio⁷, Hanno Richards⁸ and Shephard Mpofu⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…
Abstract Number: 137 • 2014 ACR/ARHP Annual Meeting
Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging
Agata Burska^1,2, Elizabeth Hensor^2,3, Jackie L. Nam³, Lukasz Kozera⁴, Richard J. Wakefield³, Paul Emery³ and Ann W Morgan⁵, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom, ²joint first authorship, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Faculty of Pharmacy and Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland, Wroclaw, Poland, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: Synovial inflammation is known to play a central role in articular cartilage degradation in rheumatoid arthritis (RA); it could be a passive marker of…
Abstract Number: 2883 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren’s Syndrome and Association with Joint Damage
Lindsay E. Brown¹, Michelle A. Frits², Christine K. Iannaccone², Michael E. Weinblatt², Nancy A. Shadick³ and Katherine P. Liao⁴, ¹Internal Medicine, Massachusetts General Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Secondary Sjögren's syndrome (sSS) is a common extra-articular manifestation of rheumatoid arthritis (RA). However, the clinical characteristics of this subgroup of patients are not…
Abstract Number: 1308 • 2013 ACR/ARHP Annual Meeting
Low Accuracy Of Radiograph Reports In Identifying Patients With Rheumatoid Arthritis In The Veterans Affairs Rheumatoid Arthritis Registry
Maria P. Martes¹, Alan R. Erickson², Ted R. Mikuls² and Grant W. Cannon³, ¹Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: The accurate interpretation of hand radiographs is critical in the diagnosis and management of rheumatoid arthritis (RA) patients. This project determined first,…
Abstract Number: 1112 • 2013 ACR/ARHP Annual Meeting
Examining Phenotypes Of Patients With Psoriasis In The Prepare Study For Similarities Between Diagnosed Psoriatic Arthritis and Those With Signs Of Subclinical Psoriatic Arthritis Detected By Imaging
Philip Mease¹, Javier Coindreau², Lotus Mallbris², Annette Szumski³ and Heather Jones², ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Progression of psoriatic arthritis (PsA) has traditionally been evaluated using clinical assessments. However, a strong relationship between clinical and radiological outcomes has been shown,…
Abstract Number: 272 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab
Tomo Nozawa, Taichi Kanetaka, Kenichi Nishimura, Masako Kikuchi, Tomomi Sato, Nodoka Sakurai, Ryoki Hara, Kazuko Yamazaki and Shumpei Yokota, Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis characterized by spiking fever, rash, and arthritis. Tocilizumab (TCZ), an anti-IL-6 receptor…
Abstract Number: 227 • 2013 ACR/ARHP Annual Meeting
Quantitative Image Analysis Of Articular Involvement In Blau Syndrome By Radiographic Calpal Length and Ultrasound Assessment
Tsuyoshi Yamatou¹, Tomohiro Kubota², Harumi Akaike¹, Yuichi Yamasaki², Yukiko Nonaka¹, Yasuhito Nerome¹, Tomoko Takezaki¹, Hiroyuki Imanaka¹, Kei Ikeda³, Naotomo Kambe⁴, Syuji Takei⁵ and Tomokazu Nagakura⁶, ¹Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ²Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁴Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan, ⁵School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁶Department of Pediatrics, House of Meguminoseibo, Usuki, Japan
Background/Purpose: Blau syndrome (Blau) is a rare auto-inflammatory disease, and it has now been shown to be caused by NOD2/CARD15 gene mutations. Clinical features of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].